Thursday, August 12, 2010

Celebrex Side Effects Lawyers

Masry & Vititoe has clients successfully seriously injured dozens of years and has represented for them the monetary compensation they deserve for their injuries repaired. Our lawyers have a dangerous drug, experience and knowledge to our clients is the most difficult cases of injury. If you take Celebrex and experienced no serious side effects, including heart or circulatory problems, heart attack or stroke, you may have a claim against the manufacturer of the drug for your injuries.

Important Information for Celebrex users: If you are currently prescribed by the drug Celebrex, you should be aware that the medication was increased to dangerous cardiovascular side effects, including strokes and heart attacks combined. It is recommended that you consult a doctor if you are looking for side effects observed.

Since its approval by the FDA in 1998 over 27 million patients, the drugs Celebrex (celecoxib have taken). These non-steroidal anti-rheumatic used for painful conditions such as arthritis, rheumatoid arthritis and adults.

Recent clinical studies have shown that Celebrex, the drug may be an increased risk of heart attack in patients suffering from stroke lead, and other cardiovascular adverse events when they are in large doses.

If you are taking or have taken Celebrex and has one of the following symptoms occur, you should contact or visit your doctor immediately:

* Hypertension
* Jaundice
* Kidney problems
* Lethargy
* Is the stool
* Unexplained weight gain
* Consistency unusual to vomit

Although Celebrex has not been delivered, the drug maker Pfizer, has been invited to participate on the label of the risks associated with the drug, including drug interactions show the change.

Celebrex is a COX-2 (non-steroidal anti-inflammatory). The plea is similar to Vioxx, withdrew voluntarily withdrawn in September because the link between heart attack and stroke, and Bextra from the market because it can cause serious cardiovascular side effects as well.

No comments:

Post a Comment